---
title: "\"Performance\" KEYMED BIO-B's annual loss slightly widened to 523 million RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280678912.md"
description: "KEYMED BIO-B announced its 2025 annual results, with revenue recorded at RMB 716 million, an increase of 67.3% year-on-year. The loss slightly widened from RMB 515 million in the previous year to RMB 523 million, with a loss per share of RMB 1.91. No final dividend will be distributed"
datetime: "2026-03-26T19:25:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280678912.md)
  - [en](https://longbridge.com/en/news/280678912.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280678912.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280678912.md) | [繁體中文](https://longbridge.com/zh-HK/news/280678912.md)


# "Performance" KEYMED BIO-B's annual loss slightly widened to 523 million RMB

KEYMED BIO-B (02162.HK) announced its 2025 annual results, with revenue recorded at RMB 716 million, an increase of 67.3% year-on-year. The loss slightly widened from RMB 515 million in the previous year to RMB 523 million, with a loss per share of RMB 1.91. No final dividend will be distributed

### Related Stocks

- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/en/quote/159615.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md)
- [KEYMED BIO-B (02162.HK)](https://longbridge.com/en/quote/02162.HK.md)

## Related News & Research

- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md)
- [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/en/news/280992698.md)
- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/en/news/281662341.md)
- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/en/news/281458440.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)